AC
Armistice Capital Portfolio holdings
AUM
$2.64B
This Quarter Return
+0.24%
1 Year Return
+0.99%
3 Year Return
+16.29%
5 Year Return
+18.04%
10 Year Return
+34.8%
AUM
$3.98B
AUM Growth
+$3.98B
(-7.4%)
Cap. Flow
-$339M
Cap. Flow
% of AUM
-8.5%
Top 10 Holdings %
Top 10 Hldgs %
28.71%
Holding
293
New
68
Increased
45
Reduced
98
Closed
73
Top Buys
| 1 |
Pfizer
PFE
|
$76.9M |
| 2 |
NVRO
NEVRO CORP.
NVRO
|
$59.9M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
$56.5M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$51.7M |
| 5 |
Keurig Dr Pepper
KDP
|
$42.1M |
Top Sells
| 1 |
GSK
GSK
|
$105M |
| 2 |
Exact Sciences
EXAS
|
$83M |
| 3 |
Organon & Co
OGN
|
$75.3M |
| 4 |
Biogen
BIIB
|
$55.3M |
| 5 |
Central Garden & Pet Class A
CENTA
|
$53.3M |
Sector Composition
| 1 | Healthcare | 68.27% |
| 2 | Consumer Staples | 10.31% |
| 3 | Technology | 7.85% |
| 4 | Consumer Discretionary | 7.66% |
| 5 | Communication Services | 3.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CANF
276
Can-Fite BioPharma
CANF
$9.63M
| – | – |
-330,000
| Closed | -$756K |
|
|
277
Central Garden & Pet Class A
CENTA
$2.11B
| – | – |
-1,364,000
| Closed | -$53.3M |
|
278
CNS Pharmaceuticals
CNSP
$3.49M
| – | – |
-124,000
| Closed | -$124K |
|
279
CVS Health
CVS
$92.7B
| – | – |
-156,000
| Closed | -$11.6M |
|
280
Interparfums
IPAR
$3.65B
| – | – |
-1,874
| Closed | -$267K |
|
|
281
Organon & Co
OGN
$2.46B
| – | – |
-3,200,000
| Closed | -$75.3M |
|
|
OTLY
282
Oatly Group
OTLY
$500M
| – | – |
-1,500,000
| Closed | -$3.63M |
|
283
Children's Place
PLCE
$112M
| – | – |
-40,000
| Closed | -$1.61M |
|
284
Papa John's
PZZA
$1.58B
| – | – |
-6,464
| Closed | -$484K |
|
|
RDHL
285
Redhill Biopharma
RDHL
$2.94M
| – | – |
-260,000
| Closed | -$1.06M |
|
286
Rekor Systems
REKR
$139M
| – | – |
-6,015,147
| Closed | -$7.52M |
|
287
RH
RH
$4.15B
| – | – |
-17,215
| Closed | -$4.19M |
|
288
Arcadia Biosciences
RKDA
$4.52M
| – | – |
-82,500
| Closed | -$616K |
|
289
RingCentral
RNG
$2.76B
| – | – |
-10,476
| Closed | -$321K |
|
290
RenovoRx
RNXT
$44M
| – | – |
-982,921
| Closed | -$3.43M |
|
291
SPDR S&P 500 ETF Trust
SPY
$655B
| – | – |
0
| – | – |
|
292
Virax Biolabs
VRAX
$2.46M
| – | – |
-1,500,000
| Closed | -$1.04M |
|
293
Verastem
VSTM
$561M
| – | – |
-2,000,000
| Closed | -$830K |
|